Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ceritinib

FDA-approved product (capsule, oral), marketed as Zykadia.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ceritinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ceritinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ceritinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

    NCT01685060 · start 2012-11-26

    Registered record
    Registry ID
    NCT01685060
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    LDK378
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-11-26
    Completion
    2016-03-29
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionLDK378
    PhasePhase 2
    Registry statusCompleted

  • Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

    NCT01634763 · start 2012-06

    Registered record
    Registry ID
    NCT01634763
    Conditions
    Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
    Interventions
    LDK378
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-06
    Completion
    2016-01
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
    InterventionLDK378
    PhasePhase 1
    Registry statusCompleted

  • A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

    NCT01283516 · start 2011-01-24

    Registered record
    Registry ID
    NCT01283516
    Conditions
    Tumors Characterized by Genetic Abnormalities of ALK
    Interventions
    LDK378
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-01-24
    Completion
    2016-05-03
    Enrolment
    304

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTumors Characterized by Genetic Abnormalities of ALK
    InterventionLDK378
    PhasePhase 1
    Registry statusCompleted

  • Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

    NCT01947608

    Registered record
    Registry ID
    NCT01947608
    Conditions
    Non-small Cell Lung Cancer (NSCLC)
    Interventions
    LDK378
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer (NSCLC)
    InterventionLDK378
    PhaseNot recorded
    Registry statusNo longer available

  • Managed Access Programs for LDK378, Ceritinib

    NCT05100134

    Registered record
    Registry ID
    NCT05100134
    Conditions
    Anaplastic Lymphoma Kinase (ALK)- Positive Tumors; Non-small Cell Lung Cancer (NSCLC)
    Interventions
    ceritinib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Lymphoma Kinase (ALK)- Positive Tumors; Non-small Cell Lung Cancer (NSCLC)
    Interventionceritinib
    PhaseNot recorded
    Registry statusNo longer available